Atlal Abusanad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Atlal Abusanad has a total of 620 co-authors. Here are the top co-authors by number of shared publications:
- Shadi Al-Khayyat
Department of Internal Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Kingdom of Saudi Arabia
3 shared publications Abdul Rahman Jazieh
Faculty of Medicine, Medical Oncology, King Abdulaziz University, Jeddah, Saudi Arabia
2 shared publications- Abdul Rahman Jazieh
Cincinnati Cancer Advisors, Cincinnati, OH
2 shared publications - Aisha Elaimi
Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah 21589, Saudi Arabia
2 shared publications - Ashraf Dallol
King Abdulaziz University
2 shared publications Assia Bensalem
Faculty of Medicine, Medical Oncology, King Abdulaziz University, Jeddah, Saudi Arabia
2 shared publications
Latest Publications
- Open Access
- 17 August 2026
- Published by Innovative Healthcare Institute in Global Journal on Quality and Safety in Healthcare
- Vol. 9 (4) , 87-91
Conflict-Related Disruption of Oncology Drug Supply in the Gulf and Measures to Maintain Cancer Care Continuity
Jqsh Global Journal on Quality and Safety in Healthcare (JQSH) aims to help healthcare professionals improve their practice by publishing quality and safety improvement outcomes in various disciplines, environments, and countries.
- 17 August 2026
- Published by Innovative Healthcare Institute in Global Journal on Quality and Safety in Healthcare
- Vol. 9 (4) , 87-91
Open AccessConflict-Related Disruption of Oncology Drug Supply in the Gulf and Measures to Maintain Cancer Care Continuity
Jqsh Global Journal on Quality and Safety in Healthcare (JQSH) aims to help healthcare professionals improve their practice by publishing quality and safety improvement outcomes in various disciplines, environments, and countries.
- Open Access
- 23 July 2026
- Published by Innovative Healthcare Institute in Journal of Immunotherapy and Precision Oncology
- Vol. 9 (3) , 120-123
ESR1-Guided Endocrine Switching in HR-Positive Metastatic Breast Cancer: From Detection to Risk-Adapted Decision in SERENA-6
- 23 July 2026
- Published by Innovative Healthcare Institute in Journal of Immunotherapy and Precision Oncology
- Vol. 9 (3) , 120-123
Open AccessESR1-Guided Endocrine Switching in HR-Positive Metastatic Breast Cancer: From Detection to Risk-Adapted Decision in SERENA-6
- Open Access
- 1 January 2026
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 19 (1) , 1283-1288
Unusual Presentation of Triple-Negative Breast Cancer in a Young Woman with Xeroderma Pigmentosum: A Case Report
Introduction: Xeroderma pigmentosum (XP) is a rare autosomal recessive DNA repair disorder, resulting from defects in nucleotide excision repair, that predisposes affected individuals to multiple cancers, particularly skin malignancies. Internal tumors including breast cancer are uncommon. Triple-negative breast cancer (TNBC) is an aggressive subtype that presents unique therapeutic challenges, particularly in XP patients where radiotherapy is contraindicated. Case Presentation: We report a 34-year-old woman with XP who presented with a 6-cm right breast mass. Histopathology revealed grade III invasive carcinoma of no special type (NST) ER-negative, PR low positivity (1–2% of cells), HER2-negative (score 0), Ki-67 >80%. BRCA1/2 testing was negative. She underwent four cycles of neoadjuvant doxorubicin/cyclophosphamide with limited response, followed by modified radical mastectomy with axillary lymph node dissection. Pathology confirmed residual 60 mm tumor with negative surgical margins and fifteen negative lymph nodes. Pathological stage: pT3pN0M0 (AJCC 8th edition). She subsequently received adjuvant paclitaxel plus carboplatin. Radiotherapy was omitted due to XP-related radiosensitivity. At 12 months, the patient remained disease-free. Conclusion: TNBC in XP is exceedingly rare and presents complex management challenges. Platinum-based chemotherapy is biologically rational given the underlying NER defect and may be particularly effective given underlying DNA repair defects, while radiotherapy avoidance necessitates surgical prioritization and PARP inhibitors may represent promising future strategies.
- 1 January 2026
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 19 (1) , 1283-1288
Open AccessUnusual Presentation of Triple-Negative Breast Cancer in a Young Woman with Xeroderma Pigmentosum: A Case Report
Introduction: Xeroderma pigmentosum (XP) is a rare autosomal recessive DNA repair disorder, resulting from defects in nucleotide excision repair, that predisposes affected individuals to multiple cancers, particularly skin malignancies. Internal tumors including breast cancer are uncommon. Triple-negative breast cancer (TNBC) is an aggressive subtype that presents unique therapeutic challenges, particularly in XP patients where radiotherapy is contraindicated. Case Presentation: We report a 34-year-old woman with XP who presented with a 6-cm right breast mass. Histopathology revealed grade III invasive carcinoma of no special type (NST) ER-negative, PR low positivity (1–2% of cells), HER2-negative (score 0), Ki-67 >80%. BRCA1/2 testing was negative. She underwent four cycles of neoadjuvant doxorubicin/cyclophosphamide with limited response, followed by modified radical mastectomy with axillary lymph node dissection. Pathology confirmed residual 60 mm tumor with negative surgical margins and fifteen negative lymph nodes. Pathological stage: pT3pN0M0 (AJCC 8th edition). She subsequently received adjuvant paclitaxel plus carboplatin. Radiotherapy was omitted due to XP-related radiosensitivity. At 12 months, the patient remained disease-free. Conclusion: TNBC in XP is exceedingly rare and presents complex management challenges. Platinum-based chemotherapy is biologically rational given the underlying NER defect and may be particularly effective given underlying DNA repair defects, while radiotherapy avoidance necessitates surgical prioritization and PARP inhibitors may represent promising future strategies.
- 13 March 2024
- Published by Springer Nature in Indian Journal of Gynecologic Oncology
- Vol. 22 (2) , 1-8
The Role of Pap Smear and HPV Vaccine in Preventing Cervical Cancer: Examining the Knowledge and Utilization Among Women from Saudi Arabia
- 13 March 2024
- Published by Springer Nature in Indian Journal of Gynecologic Oncology
- Vol. 22 (2) , 1-8
The Role of Pap Smear and HPV Vaccine in Preventing Cervical Cancer: Examining the Knowledge and Utilization Among Women from Saudi Arabia
- Open Access
- 21 December 2023
- Published by Wolters Kluwer Health in Journal of Family Medicine and Primary Care
- Vol. 12 (12) , 3368-3373
Utilizing peripheral blood inflammatory biomarker (PBIB) to predict response to systemic therapy in patients with breast cancer
Background: Inflammation is a recognized factor in cancer progression and resistance to treatments. Several studies correlated inflammation-related peripheral blood inflammatory biomarkers (PBIB) to disease progression and poor survival in various cancer types and different populations. Nonetheless, inflammation is affected by the distinctive characteristics and environmental exposure of each population. There is no prior study addressing the association of pre-treatment inflammatory markers with outcomes in patients with breast cancer (BC) from Saudi Arabia. In this study, we evaluated the prognosis of locally advanced breast cancer (LABC) in relation to several PBIB. Materials and Methods: We retrospectively analyzed the data of female patients with LABC undergoing neoadjuvant chemotherapy (NACT). Demographics, body mass index (BMI), clinicopathologic characteristics and stage of the tumor, follow-up status, and response to treatment were collected. Outcomes were evaluated in relation to pre-treatment peripheral blood indices that were grouped based on the local laboratory cutoff values. Objective response rate (ORR) was predefined and assessed according to the post-NACT magnetic resonance imaging (MRI) breast and subcategorized into complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). Results: A total of 172 female patients with BC met the eligibility criteria from January 2014 to December 2019. The mean age at diagnosis was 53.4 ± 11, and BMI was 31.2 ± 6. Left BC accounted for 54.7%, and the majority was invasive ductal carcinoma (85.5%), moderately differentiated (51%), stage III (AJCC 8 th edition) (73%), and estrogen receptor (ER)-positive tumor (79.1%). Human epidermal growth factor receptor 2 (HER2)-positive BC was reported in 32% and triple-negative breast cancer (TNBC) in 10%. Radiologic CR accounted for the majority of ORR (71.5%). Higher percentage of patients with normal red cell distribution width (RDW) of red blood cell (RBC) and low neutrophil–lymphocyte ratio (NLR) had CR with a significant P value of 0.003 and 0.014, respectively. Conclusion: Among several peripheral blood indices, RDW and NLR significantly influenced ORR. They can be explored further to potentially predict response after systemic therapy in patients with LABC. The great advantage of these biomarkers stems from their availability and affordability in routine clinical practice.
- 21 December 2023
- Published by Wolters Kluwer Health in Journal of Family Medicine and Primary Care
- Vol. 12 (12) , 3368-3373
Open AccessUtilizing peripheral blood inflammatory biomarker (PBIB) to predict response to systemic therapy in patients with breast cancer
Background: Inflammation is a recognized factor in cancer progression and resistance to treatments. Several studies correlated inflammation-related peripheral blood inflammatory biomarkers (PBIB) to disease progression and poor survival in various cancer types and different populations. Nonetheless, inflammation is affected by the distinctive characteristics and environmental exposure of each population. There is no prior study addressing the association of pre-treatment inflammatory markers with outcomes in patients with breast cancer (BC) from Saudi Arabia. In this study, we evaluated the prognosis of locally advanced breast cancer (LABC) in relation to several PBIB. Materials and Methods: We retrospectively analyzed the data of female patients with LABC undergoing neoadjuvant chemotherapy (NACT). Demographics, body mass index (BMI), clinicopathologic characteristics and stage of the tumor, follow-up status, and response to treatment were collected. Outcomes were evaluated in relation to pre-treatment peripheral blood indices that were grouped based on the local laboratory cutoff values. Objective response rate (ORR) was predefined and assessed according to the post-NACT magnetic resonance imaging (MRI) breast and subcategorized into complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). Results: A total of 172 female patients with BC met the eligibility criteria from January 2014 to December 2019. The mean age at diagnosis was 53.4 ± 11, and BMI was 31.2 ± 6. Left BC accounted for 54.7%, and the majority was invasive ductal carcinoma (85.5%), moderately differentiated (51%), stage III (AJCC 8 th edition) (73%), and estrogen receptor (ER)-positive tumor (79.1%). Human epidermal growth factor receptor 2 (HER2)-positive BC was reported in 32% and triple-negative breast cancer (TNBC) in 10%. Radiologic CR accounted for the majority of ORR (71.5%). Higher percentage of patients with normal red cell distribution width (RDW) of red blood cell (RBC) and low neutrophil–lymphocyte ratio (NLR) had CR with a significant P value of 0.003 and 0.014, respectively. Conclusion: Among several peripheral blood indices, RDW and NLR significantly influenced ORR. They can be explored further to potentially predict response after systemic therapy in patients with LABC. The great advantage of these biomarkers stems from their availability and affordability in routine clinical practice.
- Open Access
- 30 March 2022
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 8 (8) , e2100407
Cancer Burden Among Arab World Males in 2020: The Need for a Better Approach to Improve Outcome
PURPOSE: Cancer is a leading cause of increased morbidity and mortality worldwide. This work aims to study the Arab world males' cancers (AMCs) and the similarities and disparities with the world males' cancers (WMCs) from different burden points of view. MATERIALS AND METHODS: A descriptive review of the 2020 Global Cancer Observatory revealed AMCs compared with the 2020 WMCs and the 2018 AMCs. Data on the top 27 AMCs were compared among the region's countries and the world groups. RESULTS: In 2020, a total estimate of 217,203 new AMCs, 2.2% of WMCs, with an average age-standardized rate of 133.5/100,000 population, compared with 222/100,000 population of WMCs, was observed. Death estimates were 148,395, 2.7% of WMCs, with an average age-standardized rate of 95/100,000 population, compared with 120.8/100,000 population of WMCs. The five-year prevalence was observed in 442,014, 1.8% of WMCs. The average AMC mortality to incidence ratio (MIR) was 0.68, compared with 0.55 in WMCs and 0.54 in Arab females. Lung cancer was the top in incidence and mortality, whereas penile cancer was the lowest. The range of MIRs among the 27 cancer types was 0.19-0.96. CONCLUSION: The descriptive review of the 2020 males' cancers in the Arab world revealed a relatively high MIR, compared with males' cancers worldwide and the females' cancers in the Arab world. This requires further evaluation to discern the underlying causes and address them systematically. More cancer control actions are warranted.
- 30 March 2022
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 8 (8) , e2100407
Open AccessCancer Burden Among Arab World Males in 2020: The Need for a Better Approach to Improve Outcome
PURPOSE: Cancer is a leading cause of increased morbidity and mortality worldwide. This work aims to study the Arab world males' cancers (AMCs) and the similarities and disparities with the world males' cancers (WMCs) from different burden points of view. MATERIALS AND METHODS: A descriptive review of the 2020 Global Cancer Observatory revealed AMCs compared with the 2020 WMCs and the 2018 AMCs. Data on the top 27 AMCs were compared among the region's countries and the world groups. RESULTS: In 2020, a total estimate of 217,203 new AMCs, 2.2% of WMCs, with an average age-standardized rate of 133.5/100,000 population, compared with 222/100,000 population of WMCs, was observed. Death estimates were 148,395, 2.7% of WMCs, with an average age-standardized rate of 95/100,000 population, compared with 120.8/100,000 population of WMCs. The five-year prevalence was observed in 442,014, 1.8% of WMCs. The average AMC mortality to incidence ratio (MIR) was 0.68, compared with 0.55 in WMCs and 0.54 in Arab females. Lung cancer was the top in incidence and mortality, whereas penile cancer was the lowest. The range of MIRs among the 27 cancer types was 0.19-0.96. CONCLUSION: The descriptive review of the 2020 males' cancers in the Arab world revealed a relatively high MIR, compared with males' cancers worldwide and the females' cancers in the Arab world. This requires further evaluation to discern the underlying causes and address them systematically. More cancer control actions are warranted.
- Open Access
- 22 March 2022
- Published by Frontiers Media SA in Frontiers in Psychology
- Vol. 13, 845024
Prevalence and Risk Factors of Burnout Among Female Oncologists From the Middle East and North Africa
Background: Burnout (BO) is a recognized challenge among the oncology workforce. It affects both genders with a higher frequency among women. This study examined the factors contributing to the development of burnout among female oncologists from the Middle East and North Africa (MENA).Methods: An online cross-sectional survey was distributed to oncology professionals from different countries in the MENA region. The validated Maslach Burnout Inventory (MBI) of emotional exhaustion (EE), Depersonalization (DE), and Personal Achievement (PA) plus questions about demography/work-related factors and attitudes toward oncology were included. Data were analyzed to measure BO prevalence and related factors.Results: Between 10 February and 15 March 2020, 545 responses were submitted by female oncologists. The responses pre-dated the COVID-19 pandemic emergence in the region. BO prevalence was 71% among female professionals. Women aged <44 years represented 85% of the cohort. Sixty-two percent were married, 52% with children and one-third practiced a hobby. Two-thirds worked in medical oncology, worked for 25% on administrative work daily. Nearly half of the respondents (49%) expressed a recurring thought of quitting oncology and 70% had no burnout support or education. Inability to deliver optimal care was reported as distressing for career development in 82%. Factors significantly influencing the BO risk were identified. Marital status, having children, academia and years in practice did not impact the risk of BO among female oncologists from MENA.Conclusion: Female oncologists from the Middle East and North Africa (MENA) were found to have a high prevalence of BO. In this cohort, the majority of women oncology workers were young and in their early to mid-career stages. Burnout was linked to being younger, practicing in North African nations, having a heavy administrative load, and having persistent thoughts of quitting. Practicing a hobby and engaging in oncology communication, on the other hand, reduced the chance of BO. Burnout support and education, specifically for oncology women, is required.
- 22 March 2022
- Published by Frontiers Media SA in Frontiers in Psychology
- Vol. 13, 845024
Open AccessPrevalence and Risk Factors of Burnout Among Female Oncologists From the Middle East and North Africa
Background: Burnout (BO) is a recognized challenge among the oncology workforce. It affects both genders with a higher frequency among women. This study examined the factors contributing to the development of burnout among female oncologists from the Middle East and North Africa (MENA).Methods: An online cross-sectional survey was distributed to oncology professionals from different countries in the MENA region. The validated Maslach Burnout Inventory (MBI) of emotional exhaustion (EE), Depersonalization (DE), and Personal Achievement (PA) plus questions about demography/work-related factors and attitudes toward oncology were included. Data were analyzed to measure BO prevalence and related factors.Results: Between 10 February and 15 March 2020, 545 responses were submitted by female oncologists. The responses pre-dated the COVID-19 pandemic emergence in the region. BO prevalence was 71% among female professionals. Women aged <44 years represented 85% of the cohort. Sixty-two percent were married, 52% with children and one-third practiced a hobby. Two-thirds worked in medical oncology, worked for 25% on administrative work daily. Nearly half of the respondents (49%) expressed a recurring thought of quitting oncology and 70% had no burnout support or education. Inability to deliver optimal care was reported as distressing for career development in 82%. Factors significantly influencing the BO risk were identified. Marital status, having children, academia and years in practice did not impact the risk of BO among female oncologists from MENA.Conclusion: Female oncologists from the Middle East and North Africa (MENA) were found to have a high prevalence of BO. In this cohort, the majority of women oncology workers were young and in their early to mid-career stages. Burnout was linked to being younger, practicing in North African nations, having a heavy administrative load, and having persistent thoughts of quitting. Practicing a hobby and engaging in oncology communication, on the other hand, reduced the chance of BO. Burnout support and education, specifically for oncology women, is required.
- Open Access
- 1 February 2022
- Published by Innovative Healthcare Institute in Global Journal on Quality and Safety in Healthcare
- Vol. 5 (1) , 24-26
Breast Cancer Stage Migration in Saudi Arabia: Examining the Influence of Screening
In 1992, the Saudi Cancer Registry (SCR), a population-based registry, was established under the authority of the Ministry of Health (MOH). In 2014, the SCR was moved to the Saudi Health Council under the department of national registries in the National Center for Health Information. The SCR consists of the main office, which oversees data collection from all over the country through five regional offices to ensure full coverage of all healthcare facilities in the Kingdom. Cancer data are abstracted from patients' medical records based on clinical and/or histopathological diagnosis by SCR-trained cancer registrars.[1]Breast cancer is the most common malignancy among women in Saudi Arabia, with 2463 cases diagnosed between January and December of 2017. Breast cancer accounted for 17.7% of all cancers reported in Saudi citizens, and 30.9% of all cancers recorded among women of all ages.[2] SCR statistics for annual breast cancer incidence (BCI) and the percentage of each stage/year were analyzed to describe the impact of breast cancer screening on improving early-detection rates. Annual reports are available online where data from time points that corresponded to a milestone were extracted.[1] A total of 10,970 incident breast cancer cases spanning 17 years were included in the analysis; data were graphed and trends were compared. In the SCR, stages were constantly classified as localized, regional, distant, and unknown, described in its own manual (staging is the grouping of cancer cases into broad categories based on the extent of the disease staging according to the Surveillance, Epidemiology, and End Results [SEER] Summary Stage 2000).[3]The annual BCI increased by fivefold over 17 years (Fig. 1A). Until 2006–2007, there was a remarkably high percentage of regional stage, followed by a decrease in subsequent years, which was mirrored by a steady increase in localized stage. (Fig. 1B).The low percentage of early-stage disease in this review during the prescreening era (2001–2006) is likely because of delayed presentation and referral and lack of screening and awareness. Additionally, women aged 40 or older between 2001 to 2006 were born in the 1960s and preceding years when education and schooling for girls were limited, resulting in less self-care and health awareness.[4] In recent years, the incidence of localized stages has surpassed that of regional stages, and 2007–2008 marked the beginning of stage migration. (Fig. 1B). This considerable shift in stage distribution was caused by a change either in the staging system, which did not occur in this case, or an improvement in breast cancer awareness and screening programs. The breast cancer awareness–raising activity developed with the formation of the national breast cancer awareness program committee in 2003 as a non-profit initiative by the founder of the Zahra Breast Cancer Association, which was established later in 2007.[5] Several nongovernmental organizations have also founded breast screening programs in different regions of the Kingdom.[6] Interestingly, several pilot screening projects in different regions (Riyadh, Dammam, Jeddah, and Al-Qassim) were initiated as early as 1997.[7] All commonly reported low uptake rates and low cancer detection compared with western countries; however, follow-up periods were short, ranging from 2 to 5 years.[8] In 2012, the MoH initiated a nationwide Breast Cancer Early Detection (BCED) project to promote primary prevention through advertising awareness of modifiable risk factors associated with breast cancer, and secondary prevention through mammography for average-risk women who are > 40 years old.[9] Designated facilities, including mobile units across the Kingdom equipped with mammograms were made available and accessible free of charge for citizens. October is recognized nationally as the breast cancer awareness month, mirroring the international cancer calendar. Nonetheless, screening facilities are accessible throughout the year. Other nonprofit governmental and private initiatives for early detection of breast cancer are available, too. Altogether this has resulted in more detection of localized disease that matched with fewer cases of locally advanced disease. Plus, women who were 40 or older in recent years were born in the mid-1970s, when Saudi Arabia was undergoing major modernization and urbanization, which undoubtedly reflected on the population's social, educational, and health-awareness levels.[10]In addition to the overall incidence, the SCR reports cancer incidence by age group (Fig. 1C). Instead of using the mean or median age, categorical age groups are used: 15–29, 30–44, 45–59, 60–74, and 75+ years old. A sharp increase in BCI among the target age groups (i.e., the eligible age groups for screening) after the implementation of breast cancer screening should have been observed in comparison with the groups that are less likely to undergo screening (15–30 and 75+ years old) to confirm the potential effect of screening on the observed increased overall incidence. However, the lack of a clear differential BCI increase in the screening-eligible age groups neither confirms nor refutes the impact of screening on increasing BCI. Furthermore, the effect of screening might have been diluted owing to the summing of age groups creating an overlap of the cutoff age for the beginning of screening, as shown in the age group 30–44 (Fig. 1C). On the other hand, the parallel pattern of increase is highly suggestive of overall better health awareness, progress in seeking medical attention, and better accessibility to care even among elderly individuals. The caveat that SCR does not indicate the frequency of breast cancer stage incidence within each age group, which would have allowed for a more precise conclusion if documented. Although the ultimate goal of a breast cancer screening program is to reduce mortality, other...
- 1 February 2022
- Published by Innovative Healthcare Institute in Global Journal on Quality and Safety in Healthcare
- Vol. 5 (1) , 24-26
Open AccessBreast Cancer Stage Migration in Saudi Arabia: Examining the Influence of Screening
In 1992, the Saudi Cancer Registry (SCR), a population-based registry, was established under the authority of the Ministry of Health (MOH). In 2014, the SCR was moved to the Saudi Health Council under the department of national registries in the National Center for Health Information. The SCR consists of the main office, which oversees data collection from all over the country through five regional offices to ensure full coverage of all healthcare facilities in the Kingdom. Cancer data are abstracted from patients' medical records based on clinical and/or histopathological diagnosis by SCR-trained cancer registrars.[1]Breast cancer is the most common malignancy among women in Saudi Arabia, with 2463 cases diagnosed between January and December of 2017. Breast cancer accounted for 17.7% of all cancers reported in Saudi citizens, and 30.9% of all cancers recorded among women of all ages.[2] SCR statistics for annual breast cancer incidence (BCI) and the percentage of each stage/year were analyzed to describe the impact of breast cancer screening on improving early-detection rates. Annual reports are available online where data from time points that corresponded to a milestone were extracted.[1] A total of 10,970 incident breast cancer cases spanning 17 years were included in the analysis; data were graphed and trends were compared. In the SCR, stages were constantly classified as localized, regional, distant, and unknown, described in its own manual (staging is the grouping of cancer cases into broad categories based on the extent of the disease staging according to the Surveillance, Epidemiology, and End Results [SEER] Summary Stage 2000).[3]The annual BCI increased by fivefold over 17 years (Fig. 1A). Until 2006–2007, there was a remarkably high percentage of regional stage, followed by a decrease in subsequent years, which was mirrored by a steady increase in localized stage. (Fig. 1B).The low percentage of early-stage disease in this review during the prescreening era (2001–2006) is likely because of delayed presentation and referral and lack of screening and awareness. Additionally, women aged 40 or older between 2001 to 2006 were born in the 1960s and preceding years when education and schooling for girls were limited, resulting in less self-care and health awareness.[4] In recent years, the incidence of localized stages has surpassed that of regional stages, and 2007–2008 marked the beginning of stage migration. (Fig. 1B). This considerable shift in stage distribution was caused by a change either in the staging system, which did not occur in this case, or an improvement in breast cancer awareness and screening programs. The breast cancer awareness–raising activity developed with the formation of the national breast cancer awareness program committee in 2003 as a non-profit initiative by the founder of the Zahra Breast Cancer Association, which was established later in 2007.[5] Several nongovernmental organizations have also founded breast screening programs in different regions of the Kingdom.[6] Interestingly, several pilot screening projects in different regions (Riyadh, Dammam, Jeddah, and Al-Qassim) were initiated as early as 1997.[7] All commonly reported low uptake rates and low cancer detection compared with western countries; however, follow-up periods were short, ranging from 2 to 5 years.[8] In 2012, the MoH initiated a nationwide Breast Cancer Early Detection (BCED) project to promote primary prevention through advertising awareness of modifiable risk factors associated with breast cancer, and secondary prevention through mammography for average-risk women who are > 40 years old.[9] Designated facilities, including mobile units across the Kingdom equipped with mammograms were made available and accessible free of charge for citizens. October is recognized nationally as the breast cancer awareness month, mirroring the international cancer calendar. Nonetheless, screening facilities are accessible throughout the year. Other nonprofit governmental and private initiatives for early detection of breast cancer are available, too. Altogether this has resulted in more detection of localized disease that matched with fewer cases of locally advanced disease. Plus, women who were 40 or older in recent years were born in the mid-1970s, when Saudi Arabia was undergoing major modernization and urbanization, which undoubtedly reflected on the population's social, educational, and health-awareness levels.[10]In addition to the overall incidence, the SCR reports cancer incidence by age group (Fig. 1C). Instead of using the mean or median age, categorical age groups are used: 15–29, 30–44, 45–59, 60–74, and 75+ years old. A sharp increase in BCI among the target age groups (i.e., the eligible age groups for screening) after the implementation of breast cancer screening should have been observed in comparison with the groups that are less likely to undergo screening (15–30 and 75+ years old) to confirm the potential effect of screening on the observed increased overall incidence. However, the lack of a clear differential BCI increase in the screening-eligible age groups neither confirms nor refutes the impact of screening on increasing BCI. Furthermore, the effect of screening might have been diluted owing to the summing of age groups creating an overlap of the cutoff age for the beginning of screening, as shown in the age group 30–44 (Fig. 1C). On the other hand, the parallel pattern of increase is highly suggestive of overall better health awareness, progress in seeking medical attention, and better accessibility to care even among elderly individuals. The caveat that SCR does not indicate the frequency of breast cancer stage incidence within each age group, which would have allowed for a more precise conclusion if documented. Although the ultimate goal of a breast cancer screening program is to reduce mortality, other...
- 7 January 2022
- Published by Discovery Scientific Society in Medical Science
- Vol. 26 (119)
Prognostic value of pre-treatment inflammatory markers in patients with locally advanced breast cancer (LABC) from Saudi Arabia
- 7 January 2022
- Published by Discovery Scientific Society in Medical Science
- Vol. 26 (119)
Prognostic value of pre-treatment inflammatory markers in patients with locally advanced breast cancer (LABC) from Saudi Arabia